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Abstract 
Background: Stem cells constitute a group of cells which possess the ability for self-
renewal as well as the capacity of differentiation into a vast number of different cells 
within the human organism. Moreover, stem cells are able to undergo a potentially 
unlimited number of divisions and this characteristic is clinically essential. Specific fields 
of its application include treatment of diseases mainly in the field of hematology, 
orthopedics, surgery, dentistry, and neurology.  
Materials and methods: In the following work, the current knowledge concerning 
mechanisms of stem cell treatment in different parts of the digestive system with its 
diseases as well as adjacent therapy for surgery has been revised. 
Results: Stem cells therapy may be used in the treatment of various diseases of different 
parts of the digestive system. This also applies to the end part of the digestive tract 
(proctological diseases) because stem cells can be used to treat fistulas. Liposuction allows 
more recovery of mesenchymal stem cells, compared to previous bone marrow harvesting 
methods. Despite the application of stem cells in the treatment of different diseases used 
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for many years so far, the therapeutic use for the regeneration of the gastrointestinal tract is 
still rare and unfamiliar. 
Conclusions: Regenerative medicine seems to be a promising tool in medical research, 
especially when insulated cells and designed biomaterials are taken into consideration. 
Major points of discussion include type of stem cells, stem or differentiation for the 
treatment of many diseases. 
Key words: stem cell, digestive system surgery, fistula 
 
INTRODUCTION 
 Stem cells constitute a group of cells able to self-renew (i.e., have the ability to 
undergo a potentially unlimited number of divisions). Stem cells can differentiate into 
other, various types of cells. These unique attributes allow stem cells to be widely used in 
clinical medicine in at least three fields, namely I) therapy to replace lost or destroyed cell 
lines, or to modify the behaviour of other cells;  II) targets of drug therapy, and III) growth 
of differentiated tissue  for studying disease models in vitro for drug development. 
 Specific areas of stem cell application allow treatment of different diseases in the 
field of hematology, orthopedics, surgery, dentistry, and neurology [1]. Stem cells are used 
as a group of healing agents against cancer next to chemotherapy or hormone therapy (in 
leukemia, lymphoma, myelodysplatic syndrome and other hematopoetic cancers, as well as 
kidney and breast cancer or Ewing sarcoma), but they are also widely spread in aesthetic 
medicine [2-3]. Moreover, stem cells constitute great potential to be applied in regenerative 
medicine, as well. In this context, the use of stem cells falls within an interdisciplinary area 
of medicine, and combines knowledge from such branches like tissue engineering and 
molecular biology, while supporting healing, regeneration and repair of damaged tissues. 
 In this review, we want to depict the current knowledge and importance of stem 
cell therapy in digestive system surgery. 
 
HEADING 
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 Cell therapy takes advantage of human cells for the regeneration of damaged 
tissues or even the whole organs of the patient. The major problem of transplant rejection 
by the recipient organism can be significantly reduced or even eliminated  by Creating and 
transplanting organs which are grown in the laboratory from patient’s own stem cells. Stem 
cells or progenitor cells are often utilized used because of their internal regenerative 
potential for damaged tissues. The presence of stem cells in transplanted tissues increases 
angiogenesis (vascular formation), reduces inflammation, and prevents cell death. 
Furthermore, stem cells secrete numerous growth factors into their surrounding 
environment, including the vascular endothelial growth factor (VEGF), and the tumor 
growth factor (TGF) [4-5]. 
 There are several types of stem cells, as reported in Table 1. 
1. Stem cells are divided into embryonic stem cells and somatic (adult) stem cells. 
Among the embryonic stem cells there are totipotent stem cells (derived from a 
multi-cell embryo) which can differentiate into cell of any type, while the  
pluripotent stem cells can differentiate into any type of adult cell except for 
placental cells (when derived from the embryonic stem cell). Adult stem cells are 
multipotential, which may give rise to several different types of cells, usually with 
similar properties (including hematopoietic cells) or unipotent cells, which may 
give rise to only one cell type. 
Most of stem cells occur in fetal tissues and have the greatest regenerative capacity. 
Because of ethical reasons, stem cells used for treatment are received from adults. 
Mesenchymal stem cells (MCSs), which are primarily used, are isolated from almost all 
tissues (e.g., umbilical cord, periosteum, tendon, skin or muscle). MCSs are easily gained 
from adipose tissue by liposuction or by surgical excision of the tissue . This method is 
more effective than obtaining MCS from bone marrow. Intensive research done by 
academia and industry has focused on mesenchymal stromal cells (MSCs) because of their 
unique features. Full use of MSCS self-renewing ability is enabled because they MSCs can 
be easily isolated and expanded through in vitro culture [6]. 
Human mesenchymal stem cells derived from Wharton jelly (hWJ-MSC) are 
multipotent cells which can differentiate into distinct branches of cells: osteogenic, 
chondrogenic, adipogenic cells, also can trans-differentiate into neural and glial cells. hWJ-
HMSC line presents plasticity and has become an interesting and promising tool for the 
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treatment of cellular and neurogenic regenerative medicine [7]. In addition, MSCs exert 
immunomodulatory activity and can differentiate distinguish into different lines, making 
them highly attractive for clinical applications in cell therapy according to the concept of 
developmental engineering [8]. Lenas P et. al [9] studied the role of bone morphogenetic 
protein (BMP) signaling in the differentiation of adult mesenchymal progenitor cells, 
namely hMSC, towards articular cartilage. The combination of microfluidic system for 
screening soluble factors on 3D microaggregates and synthetic compounds that selectively 
and specifically silenced the BMP pathway by targeting ALK2 and ALK3 receptors, 
successfully developed a strategy effective in targeting the hMSC towards stable articular 
cartilage, both in vitro and in vivo. Thus, restricting BMP signaling can program adult 
hMSC to stable chondrogenesis [9]. 
 Stem cell therapy also has an important role in heart regeneration, i.e., 
mesenchymal stem cells (also isolated from adipose tissue), cardiac cell progenitor cells 
(CPC) and iPSC cells [10]. 
 Usage of stem cells in medicine begins in 1950s when James Alexander 
Thomson and his associates of the University of Wisconsin-Madison transplanted bone 
marrow in order to treat leukemia. Stem cell surgery started in the late 1990s, by Dr. 
Thompson of the University of Wisconsin and researchers at Johns Hopkins University 
who reestablished the acquisition from human body tissues. High hopes are placed in MCS, 
but currently the American Society of Plastic Surgeons, WHO or other organizations do 
not publish official statistics on trends associated with the use of MCS in reconstructive 
surgery [11]. 
 The mechanisms of action to use stem cells safely to regenerate the human body, 
must be further explored. The US Food and Drug Administration (FDA) in 2006 developed 
procedures to ensure the security of patients using stem cell therapy [12]. 
 So far, stem cell treatment methods have been used in more than 70 diseases, 
including hematopoetic, cardiovascular [13, 14], tumor [24], metabolic [15], 
dermatological, immune, nervous, bone-joint, digestive, and some genetic diseases. Stem 
cells can be avaiable in reconstructive surgery to replenish subcutaneous tissue defects. 
Applications include cancer treatment, radiotherapy, bone grafting, e.g. cranioplasty 
(filling of skull lid defects), filling of bone tissue defects, e.g. after resection of mandible 
tumors, cleft palate, treatment of chronic wounds (pressure sores, diabetic foot or as a 
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result of ischemia, infection), treatment of deep burns, aesthetic medicine and 
gastrointestinal surgery. 
 
APPLICATION OF STEM CELLS IN ENDODONTICS 
The pulp of a human tooth is composed of a basic substance and cellular 
components, including odontoblasts, fibroblasts and dental stem cells (DSCs), which are 
mesenchymal stem cells (MSCs). DSCs include dental pulp stem cells (DPSCs), stem cells 
from human exfoliated deciduous teeth (SHEDs), periodontal ligament stem cells 
(PDLSCs), stem cells from apical papilla (SCAP), and dental follicle progenitor cells 
(DFPCs). DPSCs are classified as specialized (postnatal) adult stem cells, differentiated by 
the effects of external factors, leading to the interruption of the process of self-renewal of 
DSCs. DPSCs, unlike the MSCs, have a multipotential character, so they can vary to at 
least three different cell lines, such as osteoblasts, endothelial cells, nerve, and fat cells. 
DPSCs were first isolated in 2000 from perivascular tissue. It is essential to take into 
consideration the source of tissue donor cells. In general, the younger and less diverse 
tissue, the better conditions for obtaining DPSCs. Fully retained third molar teeth seems to 
be the best tissue sample to use. There are no breeding conditions at the present, that would 
only increase the number of DPSCs without discriminating. The characteristic properties of 
DPSCs cells allow them to be widely used in both dental and medical research as well as 
controlled tissue regeneration. Other options for using DPSCs include treatment of 
neurodegenerative diseases such as Parkinson's disease, filling bones in orthopedics, and 
primarily in regenerative endodontics - regeneration of tissues in the newly emerging field 
of dentistry. Bone defects which are caused of malignancy, congenital deformities, traumas, 
osteoporosis, iatrogenic (surgical) and periodontal disease can be successfully treated using 
DPSCs and not only MSCs derived from bone marrow bone as it was in the past. 
 Regenerative endodontics uses stem cells to treat tooth pulp, perforation of root 
canal walls and bottom of the chamber, as well as necrosis of permanent teeth pulp with 
incomplete root formation by revascularization and regeneration. Stem cells are an 
excellent source of controlled tissue regeneration. Obtaining poorly differentiated cells is 
difficult, however possibilities of using DPSCs are very promising, therefore scientific 
research is still conduct. 
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Stem cells are also used in therapy of different organs of digestive system. Despite 
using these cells for treatment different diseases for many years, therapeutic use for the 
regeneration of gastrointestinal tract is still very rare and new [16-20]. 
 
STOMACH 
Rashed et al. studied the combined effect in rat model of mesenchymal stem cells 
gained from the bone marrow and nitric oxide inducer on injured gastric mucosa [21]. 
Administration of either MSCs, NO, or MSCS with NO may exert a therapeutic effect on 
the mucosal lesion in gastric ulcer. Effects were tested by histopathology after IV injection 
of MSCs and NO inducer. Mucosal regenerative changes and complete restoration in 
gastric ulcer occurred in the group receiving both stem cells and NO. Wang et al. studied 
using the group of 48 clean grade male Wistar rats. The aim was to establish the model of 
gastric ulcer with acetic acid.  Bone marrow mesenchymal stem cells (BMSCs) can 
accelerate ulcer healing by the secretion of VEGF, and improve the quality of ulcer cure. 
In the regenerative mucosa, the ulcer area, the mucosal thickness and the number of dilated 
glands by histology was measured by the authors. It turned out that the expression of 
vascular endothelial growth factor (VEGF) was detected at ulcerative margin, using 
immunohistochemical method [22]. 
 
LIVER 
In animal models BMSC  cured cure animal liver fibrosis. Only few studies exist 
which have been performed on humans. Zhang D. studied 60 patients with liver fibrosis 
secondary to hepatolenticular degeneration. The efficacy of treatment (penicillamine group 
vs. combination penicillamine plus BMSCs group) was evaluated based on hepatic fibrosis, 
liver function, and serological markers. Combination therapy was related to lower cytokine 
levels, meaning a significant positive effect on liver fibrosis [23]. 
 
PROCTOLOGY 
 Healing fistulas using stem cells is more accessible in proctology. Indeed, 
liposuction allows more recovery of fat cells, compared to previous bone marrow 
harvesting methods. 
 Anorectal abscesses and anal fistula are acute and chronic phase of inflammation 
of the anal crypt but they are also the result of abscess or rectal fistula. The causes include 
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inflammatory bowel disease (Crohn's disease, ulcerative colitis), trauma, foreign body, 
radiotherapy, rectal or neighboring diseases, immunosuppressive diseases and less 
common causes (endometriosis, radiation, tuberculosis etc.) [25, 26]. Fistulas surgeries 
should save sphincter muscle without inducing postoperative incontinence. To avoid 
complications treatment, however, is less radical and cause recurrences. Furthermore, 
operations that save sphincter muscle apply only to simple fistulas [28]. Patients with high, 
branched fistulas cannot be operated by traditional surgical techniques. By the stem cell 
procedure, the excision of walls and light of the fistula includes specially prepared cell 
suspension and the simultaneous stamping of the internal fistula. The cost of the extra 
procedure of picking and preparing the autogenous material for the slurry is certainly 
limited by the method. The method is effective in approximately 50% of the cases, with 
low invasiveness and repeatability [27]. Complications which can  appear are associated 
with infection of the operated site and may refer to the liposuction stage and the fistula area 
[28]. The incontinence because of anal sphincter damage may also be a complication of 
surgical treatment, especially more aggressive. Several studies have been projected to 
elaborate minimally invasive treatment of rectovaginal and anal fistulas. The properties of 
adipose-derived stem cells (ASC) significantly enhance a natural healing potency [28-32]. 
At the beginning of 21st century stem cell therapy of perianal fistulas was 
introduced. In 2005 phase I clinical study was published, reporting the treatment of 
Crohn’s disease witch autologous adipose tissue-derived MSCs  (ADSC’s) [25]. Later on 
the same department conducted phase II study,  evidencted that fistulas treated with 
ADSC’s showed higher healing rates (71%) in comparison with fibrin glue treatment (16%) 
[26]. However, only few ADSC’s treated patients remained free of recurrence for more 
than three years in long term observation [27]. 
In 2012 Herreros et al. performed a multicenter, randomized, single-blind, add-on 
clinical trial in 200 adult patients from 19 centers. Patients were randomly assigned to 
receive 20 million stem cells (group A, 64 patients), 20 million adipose-derived stem cells 
plus fibrin glue (group B, 60 patients), or fibrin glue (group C, 59 patients) after closure of 
the internal opening. Fistula healing was defined as reepithelization of the external opening 
and absence of collection >2 cm by MRI. If the fistula had not healed at 12 weeks, a 
second dose (40 million stem cells in groups A and B) was administered. Patients were 
evaluated at 24 to 26 weeks (primary end point) and at 1 year (long-term follow-up). 
Serious adverse events (SAEs) were absent. In treatment of complex fistula-in-ano, a dose 
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of 20 or 60 million adipose-derived stem cells alone or in combination with fibrin glue was 
safe treatment.  In the comparison of 3 groups No statistically significant differences were 
found [33]. 
Damian Garcia-Olmo reported similar findings [34]. They check the results of 
stem-cell therapy under a Compassionate-use Program for patients with recurrent anal 
fistulae. There were found  ten patients who had previously undergone multiple surgical 
interventions that had failed to resolve the fistula. During this research they closed of the 
internal opening and followed by local implant of stem cells in the fistula-tract wall. The 
main cell type selected for implant was autologous expanded adipose-derived stem cells. 
Outcome at 8 weeks was classified as response or partial response. Evaluation one year 
after the intervention confirmed if complete healing of the fistula occurred. No adverse 
reactions or complications related to stem-cell therapy occurred during the study period. 
Both studies independently of each other proved that stem cells are safe and useful for 
treating anal fistulae [34,35. 
 A recent multi-center phase III study by Panes et al. showed that 50% of the 
patients receiving ADSC’s treatment had 6 months remission, compared to 34% of patients 
on placebo treatment [36]. Dietz et al. showed complete recovery in 83% of treated 
patients [37]. A meta-analysis performed by Lightner et al., which analyzed severe phase 
I,II and III trials, reports healing rates ranged from 27%-83%, with positive early results in 
more than half of analyzed studies [38]. 
 
GASTROINTESTINAL TRACT 
 Recently, results of first human Phase 1/2 trial using genetically modified MSCs 
for treatment of adenocarcinomas of the hepatobiliary and gastrointestinal tract was 
published. During the progression of the tumor, MSCs are recruited into the stroma of the 
tumor. That process ause its growth and metastasis [39-42]. Mesenchymal stem cells have 
several abilities, which make them perfect vehicle for tumor directed therapy. They have 
the ability to migrate into deep layers of the tumor microenvironment and differentiate into 
the tumor stroma cells. Moreover, they have low immunogenicity and can be easily 
isolated and multiplied and [43-46]. The therapy was confirmed to be acceptably safe and 
tolerable, which was consistent with Phase 1 study results [47]. Study presented signs of 
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activity with stable disease in five of ten patients, however no impact on tumor markers 
and size was observed [48]. 
 
WOUNDS 
 Process of wound healing involves multiple growth factors and stem cells and 
should be studied both in terms of research and clinical relevance. One of the surgical 
challenge  is the problematic wound healing and ulceration in radiation-damaged tissue. 
These problems may appear in non-healing surgical wounds, especially in patients with 
cachexia or with cancers after radiotherapy. Some ongoing clinical trials with growth 
factors have already produced very promising therapeutic results which can be used in 
earlier mentioned cases [50-54]. 
 Grafting fat tissue in an irradiated area can improve the quality of the skin and 
has regenerative effects. The case study by Mohan and Singh describes presents healing of 
a chronic ulcer resistant to other ways of treatment using fat tissue transfer (which contains 
adipose-derived stem cells). A 67-year-old woman lady with a chronic, non-healing ulcer 
in her leg had a squamous cell carcinoma excised, followed by radiotherapy. After every 
od multipleexcisions,ulcer continued to cause symptoms. The patient underwent a wide 
local excision and split-thickness skin grafting. Afterwards fat was infiltrated around and 
under the ulcer. In the histological examination there was a post-radiation dermatitis ulcer 
with no evidence of malignancy. After a period in which dressings were used, a reduction 
in ulcer size were observed and more fat was infiltrated around the lesion. Two months 
later, the ulcer had been fully healed without recurrence. This case shows the potential of 
adipose tissue to improve damaged skin. Its use will be able to change the need for 
complex surgical procedures [49]. 
 This kind of cases prove that modern therapies, especially cellular and protein 
therapies, are the future of skin treatments such as burns and chronic wounds. The 
increased amount of growth factors associated with inflammation, which is often seen in 
chronic wounds, may also carry a potential risk of cancer transformation. Cellular and 
humoral mechanisms of neoplasm has many similarities with physiological wound healing 
(stem cell involvement, inflammation strong proliferation, similar growth factors,). 
However, proper wound healing is strictly controlled and after it is completed, it begins a 
 10 
natural self-limitation process which is completely different compared to the neoplasm 
process [50-54]. 
 
SUMMARY 
 One of the most promising directions in medical research is regenerative 
medicine, which main tools are insulated cells and specially designed biomaterials. 
Discussions in recent years deal with the type of stem, stem or differentiation that will be 
most useful in the treatment of many diseases but there is no clear answer.However, it is 
obvious that different types of cells will play a different role in relation to the tasks they 
are supposed to fulfill. Bone marrow have been introduced into clinical practice cells faster 
than other types of cells. The ability to differentiate mesenchymal bone marrow stem cells 
into many cell types makes their use an attractive cell source for tissue and organ 
regeneration. However, the challenge still remains to effectively differentiate MSC cells 
towards the desired cell lines and to maintain the phenotype of previously differentiated 
cells. Fully verifiable results of stem cell treatment are still growing [53,54]. 
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Table 1. Various types of stem cells 
Embryonic 
stem cells 
Adult (somatic) 
stem Cells 
Induced 
Pluripotent Stem 
Cells (Artificial) 
Fetal Stem Cells Amniotic 
Stem Cells 
Totipotent Hematopoietic 
Stem Cells 
- Proper Fetal 
Stem Cells 
- 
Pluripotent Mesenchymal Stem 
Cells 
- Extraembryonic 
Fetal Stem Cells 
- 
Multipotent Neural Stem Cells - - - 
Oligopotent Epithelial Stem 
Cells 
- - - 
Unipotent Skin Stem Cells - - - 
 
 
